BCL2 and cancer: In particular, CDK9 emerged as a druggable target for the development of cancer therapeutics, due to its crucial role in the transcriptional regulation of both short-lived anti-apoptotic proteins and oncogenes, such as BCL2/6 and MYC, critical for the survival of transformed cells[66].